ASH 2013: Highlights in Chronic Myelogenous Leukemia


Prognostic Value of Response Rates from Baseline by Three Months and the Four-Year Update from the ENESTnd and DASISION Trials: Safety and Efficacy of Second-Generation TKIs versus Imatinib for Newly Diagnosed CP-CML
Neil P. Shah, MD, PhD, (Moderator) with Jorge Eduardo Cortes, MD

Begin


Highlights from Targeting Tyrosine Kinase Receptors
Neil P. Shah, MD, PhD, (Moderator) with Michael Deininger, MD, PhD

Begin


TKI Discontinuation Studies and Insights into Predicting Which Patients May Relapse After Discontinuation: Euro-SKI and DADI Trials
Neil P. Shah, MD, PhD, (Moderator) with Satu Mustjoki, MD, PhD

Begin


Follow-up of the Phase II PACE Trial and Clinical Impact of Dose Modification on Response to Ponatinib in Patients with Chronic Phase Chronic Myeloid Leukemia
Neil P. Shah, MD, PhD, (Moderator) with Javier Pinilla-Ibarz, MD, PhD

Begin


Highlights of Alternative Approaches to Eradicating the Malignant Clone in Chronic Myeloid Leukemia: Tyrosine Kinase Inhibitor Combinations and Beyond
Neil P. Shah, MD, PhD, (Moderator) with Richard A. Van Etten, MD, PhD

Begin

For an additional highlight from ASH 2013 please view the following commentary ELN and NCCN Guideline Updates, Recommendations for Monitoring Response to Therapy and ENESTnd Trial


FDA Safety Alert
UPDATED 12/20/2013. Ponatinib has been reinstated by the US FDA with update to the labeling and a REMS program. Read More Here U.S. Resumption of Marketing and Commercial Distribution of Ponatinib in Refractory Philadelphia-Positive Leukemias